A case of fulminant meningococcemia: it is all in the complement
KL Hawkins, M Hoffman, S Okuyama… - Case Reports in …, 2017 - Wiley Online Library
Eculizumab is a novel monoclonal antibody that inhibits complement‐mediated hemolysis in
patients with paroxysmal nocturnal hemoglobinuria (PNH). Complement deficiency is a well …
patients with paroxysmal nocturnal hemoglobinuria (PNH). Complement deficiency is a well …
Extravascular hemolysis due to C3-loading in patients with PNH treated with eculizumab: defining the clinical syndrome
CE McKinley, SJ Richards, T Munir, M Griffin… - 2017 - ashpublications.org
Introduction Complement-mediated intravascular hemolysis in patients with paroxysmal
nocturnal hemoglobinuria (PNH) is effectively prevented by the terminal-complement …
nocturnal hemoglobinuria (PNH) is effectively prevented by the terminal-complement …
Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria
S Chonat, A Kulagin, A Maschan, M Bartels… - Blood …, 2024 - ashpublications.org
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disease of uncontrolled
terminal complement activation leading to intravascular hemolysis, thrombotic events …
terminal complement activation leading to intravascular hemolysis, thrombotic events …
A patient with paroxysmal nocturnal hemoglobinuria being treated with eculizumab who underwent laparoscopic cholecystectomy: report of a case
M Moriyama, T Nagata, I Yoshioka, I Hashimoto… - Surgical Case …, 2015 - Springer
Paroxysmal nocturnal hemoglobinuria (PNH) is acquired hemolytic anemia characterized by
symptoms such as anemia and hemoglobinuria. In recent years, eculizumab as an anti …
symptoms such as anemia and hemoglobinuria. In recent years, eculizumab as an anti …
Paroxysmal nocturnal hemoglobinuria turning Coombs-positive
A Röth, S Peine, U Dührsen - International journal of hematology, 2010 - Springer
Paroxysmal nocturnal hemoglobinuria (PNH) represents a Coombs-negative hemolytic
anemia. Due to mutations of the PIG-A gene, the affected progeny cells are deficient in all …
anemia. Due to mutations of the PIG-A gene, the affected progeny cells are deficient in all …
Paroxysmal nocturnal hemoglobinuria with a distinct molecular signature diagnosed ten years after allogenic bone marrow transplantation for acute myeloid leukemia
A Santagostino, L Lombardi, G Dine… - Case Reports in …, 2019 - Wiley Online Library
Paroxysmal nocturnal hemoglobinurea (PNH) is a rare disorder of complement regulation
due to somatic mutation of PIGA (phosphatidylinositol glycan anchor) gene. We herewith …
due to somatic mutation of PIGA (phosphatidylinositol glycan anchor) gene. We herewith …
[HTML][HTML] Acute myeloid leukemia and fatal Scedosporium prolificans sepsis after eculizumab treatment for paroxysmal nocturnal hemoglobinuria: a case report
M Hanmantgad, R Nog, K Seiter - Stem Cell Investigation, 2017 - ncbi.nlm.nih.gov
Eculizumab has become the standard of care for patients with paroxysmal nocturnal
hemoglobinuria (PNH). As more patients are treated, the long-term outcomes of these …
hemoglobinuria (PNH). As more patients are treated, the long-term outcomes of these …
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
RSM Wong - Therapeutic Advances in Hematology, 2022 - journals.sagepub.com
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease
characterized by complement-mediated hemolysis, thrombosis, and various degrees of …
characterized by complement-mediated hemolysis, thrombosis, and various degrees of …
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
Background We tested the safety and efficacy of eculizumab, a humanized monoclonal
antibody against terminal complement protein C5 that inhibits terminal complement …
antibody against terminal complement protein C5 that inhibits terminal complement …
[HTML][HTML] Breakthrough hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: results of a 52-week extension from two phase …
A Hill, CI Piatek, RP de Latour, LLL Wong, RA Wells… - Blood, 2019 - Elsevier
INTRODUCTION In patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH)
receiving eculizumab, approximately 11%-27% may experience breakthrough hemolysis …
receiving eculizumab, approximately 11%-27% may experience breakthrough hemolysis …